Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit against Actinium Pharmaceuticals, Inc.
On March 28, 2025, Bronstein, Gewirtz & Grossman, LLC, a leading national securities litigation law firm, announced the filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE:ATNM) and certain of its officers. The lawsuit alleges that the Company and its officers violated the federal securities laws during the Class Period, which spans from March 31, 2022, to August 2, 2024.
Class Definition
The lawsuit aims to recover damages on behalf of all persons and entities that purchased or otherwise acquired Actinium securities during the Class Period. These investors may be eligible to participate in the class action and share in any potential recovery.
Allegations against Actinium and its Officers
The complaint filed by Bronstein, Gewirtz & Grossman, LLC alleges that Actinium and certain of its officers made false and misleading statements regarding the Company’s business, operational, and financial prospects. Specifically, the lawsuit alleges that the defendants failed to disclose material information concerning the Company’s clinical trial results, regulatory developments, and financial condition.
Impact on Individual Investors
If you purchased Actinium securities during the Class Period, you may be eligible to participate in the class action lawsuit. The potential recovery could include damages for financial losses incurred as a result of the alleged securities law violations. It is essential to consult with a securities attorney to determine your eligibility and potential recovery.
Global Implications
The class action lawsuit against Actinium Pharmaceuticals, Inc. could have far-reaching implications for the biotechnology industry as a whole. It highlights the importance of transparency and accurate reporting for publicly traded companies. The outcome of this lawsuit could set a precedent for future securities litigation cases and potentially influence investor confidence in the sector.
Conclusion
The filing of a class action lawsuit against Actinium Pharmaceuticals, Inc. by Bronstein, Gewirtz & Grossman, LLC, alleging securities law violations during the Class Period, could result in significant financial consequences for the Company and its officers. Individual investors who purchased Actinium securities during the Class Period may be eligible to participate in the lawsuit and potentially recover damages. The lawsuit’s outcome could also have global implications for the biotechnology industry, emphasizing the importance of transparency and accurate reporting for publicly traded companies.
- Bronstein, Gewirtz & Grossman, LLC files class action lawsuit against Actinium Pharmaceuticals, Inc.
- Allegations of securities law violations against the Company and certain officers.
- Class Period spans from March 31, 2022, to August 2, 2024.
- Individual investors who purchased Actinium securities during the Class Period may be eligible to participate in the lawsuit.
- Outcome of the lawsuit could have global implications for the biotechnology industry.
